Diabetes

February 10, 2018

Molecular therapy for Metabolic diseases: Rolipram, a phosphodiesterase-4 inhibitor and an investigational drug for depression, autoimmune diseases, Alzheimer’s disease,cognitive enhancement,spinal cord injury, asthma and COPD, increases the expression of Caveolin-1, stabilizes insulin receptor, promotes insulin sensitivity, increases vasorelaxation, and decreases the risk of hyperglycemia and TIIDM via up regulation of its target gene.., 10/February/2018, 6.55 am

Introduction: What they say A study from the Institute for Molecular Systems Biology, ETH Zurich, Zurich, Switzerland shows that “MicroRNAs 103 and 107 regulate insulin sensitivity.” This study was published, in the June […]
February 8, 2018

Molecular therapy for body weight control, energy homeostasis and TIIDM: A pharmaceutical mixture encompassing 17α-Estradiol and Aspirin  inhibits DNA methyltransferase 3a (Dnmt3a) expression, increases FGF21 expression, augments insulin sensitivity, increases glucose tolerance, and protects from diet-induced obesity and TIIDM, via up regulation of its target gene, 8/February/2018, 11.03 pm

Introduction: What they say  A study from Nutritional Sciences and Toxicology Department, University of California, Berkeley, Berkeley, United States shows that “Dnmt3a is an epigenetic mediator […]
February 7, 2018

Molecular therapy for body weight control, energy homeostasis and TIIDM: A pharmaceutical mixture encompassing Nordihydroguaiaretic acid and Aspirin  inhibits DNA methyltransferase 3a (Dnmt3a) expression, increases FGF21 expression, augments insulin sensitivity, increases glucose tolerance, and protects from diet-induced obesity and TIIDM, via up regulation of its target gene, 7/February/2018, 10.32 pm

Introduction: What they say  A study from Nutritional Sciences and Toxicology Department, University of California, Berkeley, Berkeley, United States shows that “Dnmt3a is an epigenetic mediator […]
February 6, 2018

Molecular therapy for body weight control, energy homeostasis and TIIDM: D-β-Hydroxybutyrate (D-βHB) increases REV-ERB and its down stream target genes, inhibits lipid accumulation, improves dyslipidemia and insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM via up regulation of its target gene, 6/February/2018, 6.58 am

Introduction: What they say A study from the Department of Molecular Therapeutics, The Scripps Research Institute, Jupiter, Florida 33458, USA shows that “Regulation of circadian behaviour […]